Background　Transcatheter　arterial　chemoembolization　combined　with　lenvatinib　and　PD-1　inhibitors　(triple　therapy)　is　a　promising　therapy　for　unresectable　hepatocellular　carcinoma　(uHCC).　We　aimed　to　assess　the　characteristics　and　identify　predictors　of　long-term　survival　(LTS)　in　advanced　uHCC　treated　with　triple　therapy.Methods　Retrospectively　reviewed　patients　with　uHCC　who　underwent　triple　therapy　between　June　2018　and　May　2023　at　8　hospitals　in　China.　LTS　was　defined　as　an　overall　survival　(OS)　＞=　24　months.　Kaplan-Meier　curves　were　used　to　estimate　survival.　Univariate　and　multivariate　logistic　regression　analyses　were　performed　to　identify　predictors　of　LTS.Results　A　total　of　110　patients　were　included　in　this　study.　With　a　median　follow-up　of　31.3　months,　the　median　OS　and　progression-free　survival　for　the　entire　cohort　were　17.9　months　(95%　confidence　interval　[CI],　13.8-21.2)　and　11.8　months　(95%　CI,　9.9-15.3),　respectively.　Thirty-nine　(35.5%)　patients　had　LTS,　with　36-　and　48-month　OS　rates　of　95.8%　and　82.1%,　respectively.　In　contrast,　the　median　OS　for　patients　with　non-LTS　was　10.9　months　(95%　CI,　9.9-13.2).　The　independent　predictors　of　LTS　were　the　absence　of　portal　vein　tumor　thrombus　(odds　ratio　[OR],　13.71;　95%　CI,　3.19-88.08;　p　＜　.001),　absence　of　extrahepatic　metastasis　(OR,　7.81;　95%　CI,　2.76-25.82;　p　＜　.001),　and　platelet-albumin-bilirubin　grade　1　(OR,　3.15;　95%　CI,　1.17-9.15;　p　=　.023).Conclusions　The　absence　of　portal　vein　tumor　thrombus,　absence　of　extrahepatic　metastasis,　and　platelet-albumin-bilirubin　grade　1　were　significantly　associated　with　LTS.　These　findings　help　guide　treatment　decisions　in　advanced　uHCC.